Discover
ACHL
Achilles Therapeutics plc
1.48
undefined x undefined
undefined x undefined
bid
ask
+
0.01
0.68%
04:00 PM
| Ytd | 29.82% | |
| 1y | 14.73% |
1.45
day range
1.50
52 week range
| Open | 1.48 | Prev Close | 1.47 | Low | 1.45 | High | 1.50 | Mkt Cap | N/A |
| Vol | 1.20M | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -0.61 |
| Beta | 1.34 | Short Ratio | 1.69 | Inst. Own | 59.30% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 0.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | -0.41 | -0.48 | -0.07 | -17.07% |
| 2024-08-14 | 2024-06 | -0.41 | N/A | N/A | N/A |
| 2024-08-14 | 2024-06 | -0.41 | -0.41 | N/A | N/A |
| 2024-05-08 | 2024-03 | -0.46 | -0.3 | 0.16 | 34.78% |
| 2024-05-08 | 2024-03 | -0.46 | N/A | N/A | N/A |
| 2024-04-04 | 2023-12 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-04-05 | Chardan Capital | Upgrade | Buy | Buy |
| 2024-04-05 | Piper Sandler | Downgrade | Overweight | Neutral |
| 2023-12-14 | B of A Securities | Downgrade | Buy | Underperform |
| 2023-08-07 | Chardan Capital | Upgrade | Buy | Buy |
| 2023-05-11 | Chardan Capital | Upgrade | Buy | Buy |
| 2022-12-07 | Chardan Capital | Upgrade | Buy |
Profile
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Syncona Portfolio Ltd | 11.09M | 12.64M | 26.98% |
| 2024-09-29 | BML Capital Management, LLC | 4.10M | 4.67M | 9.98% |
| 2024-09-29 | Fcpm III Services B.v. | 2.39M | 2.72M | 5.82% |
| 2024-09-29 | Redmile Group, LLC | 1.61M | 1.83M | 3.91% |
| 2024-09-29 | Vestal Point Capital, LP | 1.50M | 1.71M | 3.65% |
| 2024-09-29 | Ikarian Capital, LLC | 1.44M | 1.65M | 3.51% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 21.59K | 24.61K | 0.05% |
| 2024-09-29 | Blackstone Alternative Multi-Strategy Fund | 100.00 | 113.00 | 0.00% |